Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like ParticlesPaul Goepfert, Harriet L. Robinson, Lilin Lai et al.|The Journal of Infectious Diseases|2011Cited by 177
Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120Nina D. Russell, Lawrence Corey, Barney S. Graham et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2006Cited by 104
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersPaul Goepfert, Thomas G. Evans, Georgia D. Tomaras et al.|Vaccine|2006Cited by 93
High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human SubjectsPaul Goepfert, Helen Horton, M. Juliana McElrath et al.|The Journal of Infectious Diseases|2005Cited by 65
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trialAngela R Branche, Kuleni Abebe, Nadine Rouphael et al.|Nature Medicine|2023Cited by 56